Infections and infestations
FDA approves Basilea’s antibiotic Zevtera for three indications
April 4, 2024Medical Communications Basilea Pharmaceutica, FDA, Infections and infestations, Zevtera, antibiotic
Basilea Pharmaceutica has announced that the US Food and Drug Administration (FDA) has approved Zevtera (ceftobiprole medocaril sodium for injection), …
FDA approves Roche’s test for malaria in blood donors
April 2, 2024Business Services FDA, Infections and infestations, blood donation, malaria
Roche has announced that the US Food and Drug Administration (FDA) has approved its cobas Malaria test for use on …
EC approves Pfizer’s Prevenar 20 to protect paediatric patients against pneumococcal disease
March 13, 2024Research and Development EC, EMA, Infections and infestations, Prevnar 20, pneumococcal disease
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Prevenar 20, the company’s 20-valent pneumococcal conjugate …
Spero Therapeutics’ bacterial infection treatment gains FDA IND clearance
February 29, 2024Medical Communications FDA, Infections and infestations, Spero Therapeutics, bacterial infections, investigational new drug
Spero Therapeutics has announced that it has gained US Food and Drug Administration (FDA) clearance for the investigational new drug …
GSK shares positive results from phase 3 trial for gonorrhoea treatment
February 27, 2024Research and Development GSK, Infections and infestations, antibiotic, clinical trial, gonorrhoea
GSK has announced positive headline results from its phase 3 EAGLE-1 trial for gepotidacin, its potential first-in-class oral antibiotic with …
EMA to review GSK’s Arexvy for RSV prevention in adults aged 50-59
January 29, 2024Medical Communications Arexvy, EMA, Infections and infestations, RSV
GSK has announced that the European Medicines Agency (EMA) has accepted the company’s regulatory application to expand the use of …
UKHSA warns of measles outbreak
January 22, 2024Medical Communications Infections and infestations, MMR, UKHSA, measles, vaccination
The UK Health Security Agency (UKHSA) has warned that further outbreaks of measles could spread to other towns and cities …
NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19
January 12, 2024Medical Communications COVID-19, Infections and infestations, NICE
The National Institute for Health and Care Excellence (NICE) has announced that it has expanded the guidance around which patients …
Venatorx and Menarini enter commercial agreement for cefepime-taniborbactam
January 11, 2024Sales and Marketing Infections and infestations, Menarini Group, Venatorx Pharmaceuticals, cefepime-taniborbactam, collaboration
Venatorx Pharmaceuticals and Menarini Group have announced that they have entered into a commercial agreement valid in 96 countries in …
GSK shares data from global shingles survey
December 1, 2023Medical Communications GSK, Infections and infestations, data, shingles
GSK has announced data from its new global survey about shingles. The data suggests that there are some significant gaps …
FDA grants breakthrough device designation to Inflammatix’s TriVerity Acute Infection and Sepsis Test System
November 29, 2023Research and Development FDA, Infections and infestations, Inflammatix, TriVerity, infection, sepsis
Inflammatix has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company’s lead …
GSK enters agreement for license for JNJ-3089 for development of bepirovirsen
November 2, 2023Medical Communications Arrowhead Pharmaceuticals, GSK, Infections and infestations, Janssen, hepatitis B
GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen Pharmaceuticals, a Johnson & Johnson …
Acurx Pharmaceuticals announces positive data from phase 2b trial for C. difficile infection treatment
October 3, 2023Research and Development Acurx Pharmaceuticals, C. difficile, Infections and infestations, clinical trial, infection
Acurx Pharmaceuticals has announced that it has discontinued its phase 2b clinical trial of its lead antibiotic candidate, ibezapolstat, for …
Vaxart shares topline data from phase 2 study of norovirus vaccine candidate
September 8, 2023Research and Development Infections and infestations, Vaccine, Vaxart, norovirus
Vaxart has announced topline data from its phase 2 challenge study which assessed its oral tablet monovalent norovirus vaccine candidate. …
Valneva and Pfizer share positive results from phase 2 trial for Lyme disease vaccine candidate
September 7, 2023Medical Communications Infections and infestations, Pfizer, Vaccine, Valneva, clinical trial, lyme disease
Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
